Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Nadofaragene firadenovec |
Trade Name | Adstiladrin |
Synonyms | rAd-IFN|rAd-IFN-2b|Nadofaragene firadenove-vncg|SCH 721015|SCH721015|SCH-721015 |
Drug Descriptions |
Adstiladrin (nadofaragene firadenovec) is a recombinant adenovirus that encodes IFN alpha 2B, which may have potential antitumor activity (PMID: 11922775). Adstiladrin (nadofaragene firadenovec) is FDA approved for use in patients with high-risk BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ (FDA.gov). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C71011 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Celecoxib + Gemcitabine + Nadofaragene firadenovec | Celecoxib Gemcitabine Nadofaragene firadenovec | 0 | 1 |
Docetaxel + Gemcitabine + Nadofaragene firadenovec | Docetaxel Gemcitabine Nadofaragene firadenovec | 0 | 1 |
Nadofaragene firadenovec | Nadofaragene firadenovec | 0 | 3 |
Nadofaragene firadenovec + Pembrolizumab | Nadofaragene firadenovec Pembrolizumab | 0 | 1 |